New York – 18 August, 2023 – Distinguished interventional oncologist Dr. Jeff Geschwind has made significant strides in the field of hepatocellular carcinoma (HCC) treatment through his groundbreaking work on the application of Anti-Glycolytic Drugs. His latest review covers both systemic and locoregional treatment options, offering new avenues for combating this aggressive cancer.
Hepatocellular Carcinoma is a formidable global health concern with limited therapeutic options. Dr. Geschwind’s research is revolutionizing treatment paradigms by focusing on the disruption of glycolysis, a crucial metabolic pathway used by cancer cells for energy production and proliferation. By targeting this pathway with Anti-Glycolytic Drugs, Dr. Geschwind aims to curtail cancer growth and enhance the efficacy of existing treatment modalities.
In this latest review, Dr. Geschwind explores the potential of both systemic and locoregional administration of Anti-Glycolytic Drugs. This innovative approach holds promise in not only inhibiting tumor progression but also minimizing the adverse effects associated with traditional treatments. The combination of systemic drug delivery to target metastatic lesions and locoregional administration for localized tumors demonstrates the versatility of this novel treatment strategy.
Dr. Geschwind’s research marks a significant step forward in personalized medicine for HCC patients. His work has the potential to transform the landscape of liver cancer treatment, offering renewed hope and improved outcomes for patients around the world.
“It’s an exciting time in the field of oncology,” says Dr. Geschwind. “Our research brings us closer to addressing the unmet needs of HCC patients and expanding the therapeutic options available to them. By targeting the metabolic vulnerabilities of cancer cells, we are opening up new avenues for effective treatment.”
As an internationally recognized authority in interventional oncology and a prolific researcher, Dr. Jeff Geschwind continues to make invaluable contributions to the medical community. His dedication to advancing liver cancer treatment showcases his commitment to improving patient lives and underscores the importance of innovative approaches in oncology.
For media inquiries or to learn more about Dr. Jeff Geschwind’s research on Anti-Glycolytic Drugs in the Treatment of Hepatocellular Carcinoma, please contact:
About Dr. Jeff Geschwind
Dr. Jeff Geschwind is a distinguished interventional radiologist and researcher known for his pioneering work in interventional oncology and liver cancer treatment. Formerly at Johns Hopkins and Yale, he is now the medical director of Oncology at USA Clinics and Oncology Centers and the Medical Director for Oncology and Image-Guided Therapy at NAMSA the largest device-oriented CRO in the world. Dr. Geschwind has published nearly 300 scientific manuscripts and has received numerous awards for his contributions to the fields of interventional radiology and oncology. Dr. Geschwind’s research focuses on developing innovative approaches to cancer treatment, with a particular emphasis on hepatocellular carcinoma.
Contact
Jeff Geschwind
jeanfrancoisgeschwind@gmail.com
+1 410 446 8071
https://jeffgeschwind.com
Media Contact
Company Name: Dr. Jeff Geschwind
Contact Person: Dr. Jeff Geschwind
Email: Send Email
Phone: +1 410 446 8071
Country: United States
Website: https://jeffgeschwind.com